4.8 Article

Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy

期刊

CELL METABOLISM
卷 31, 期 6, 页码 1078-+

出版社

CELL PRESS
DOI: 10.1016/j.cmet.2020.04.008

关键词

-

资金

  1. Centre of Excellence from Academy of Finland [307431]
  2. academy grants [307592, 303349, 286359, 272376, 314383, 266286]
  3. Sigrid Juselius Foundation
  4. United Mitochondrial Disease Foundation
  5. Finnish Medical Foundation
  6. Novo Nordisk Foundation
  7. Gyllenberg Foundation
  8. Finnish Diabetes Research Foundation
  9. Finnish Foundation for Cardiovascular Research
  10. HiLife/University of Helsinki
  11. Government Research Funds (Helsinki University Hospital)
  12. Academy of Finland (AKA) [307431, 307431] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

NAD(+) is a redox-active metabolite, the depletion of which has been proposed to promote aging and degenerative diseases in rodents. However, whether NAD(+) depletion occurs in patients with degenerative disorders and whether NAD(+) repletion improves their symptoms has remained open. Here, we report systemic NAD(+) deficiency in adult-onset mitochondrial myopathy patients. We administered an increasing dose of NAD(+) booster niacin, a vitamin B3 form (to 750-1,000 mg/day; clinicaltrials.gov NCT03973203) for patients and their matched controls for 10 or 4 months, respectively. Blood NAD(+) increased in all subjects, up to 8-fold, and muscle-NAD(+) of patients reached the level of their controls. Some patients showed anemia tendency, while muscle strength and mitochondrial biogenesis increased in all subjects. In patients, muscle metabolome shifted toward controls and liver fat decreased even 50%. Our evidence indicates that blood analysis is useful in identifying NAD(+) deficiency and points niacin to be an efficient NAD(+) booster for treating mitochondrial myopathy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据